SHARE online support communities for patients with ovarian cancer, breast cancer, and metastatic breast cancer.
It's easier than ever to connect with other patients and survivors and find relevant information and support through SHARE's online support communities for breast cancer, ovarian cancer, and metastatic breast cancer! The communities are hosted on HealthUnlocked, the social network for health.
Members can write posts that ask for advice, tips, or encouragement about a particular issue they’re facing in their treatment. Or, they can offer up suggestions for resources they’ve found helpful. HealthUnlocked makes it easier than ever to find relevant information, and joining the communities is simple and anonymous. There are no advertisements, and there is no spam. Instead, the site offers suggestions of content or connections that are relevant to people at different stages of their cancer experiences.
Interested in Joining?
Choose your community:
Click "Sign Up," and enter a username, your email, and a password.
Once on the community page, click "Follow."
We're so excited to be able to offer a safe, welcoming space for women to get the support and information they need online. See you there!
Olaparib Plus Chemo May Not Improve Outcomes vs Chemo Alone in BRCA Wild-Type TNBC
April 23rd 2024Patients with BRCA wild-type triple-negative breast cancer treated with olaparib on a gap schedule with chemotherapy did not experience improved responses compared with chemotherapy alone in the neoadjuvant setting.
FDA Grants Accelerated Approval to Fam-Trastuzumab Deruxtecan-Nxki in HER2+ Solid Tumors
April 5th 2024The FDA granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu) for patients with unresectable or metastatic HER2-positive solid tumors who have received prior systemic treatment.
Olaparib Plus Chemo May Not Improve Outcomes vs Chemo Alone in BRCA Wild-Type TNBC
April 23rd 2024Patients with BRCA wild-type triple-negative breast cancer treated with olaparib on a gap schedule with chemotherapy did not experience improved responses compared with chemotherapy alone in the neoadjuvant setting.
FDA Grants Accelerated Approval to Fam-Trastuzumab Deruxtecan-Nxki in HER2+ Solid Tumors
April 5th 2024The FDA granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu) for patients with unresectable or metastatic HER2-positive solid tumors who have received prior systemic treatment.
Olaparib Plus Chemo May Not Improve Outcomes vs Chemo Alone in BRCA Wild-Type TNBC
Less Than Half of Recently Approved Cancer Drugs Show a Clinical Benefit
Cadonilimab Plus Chemo Provides Survival Benefit in Gastric/GEJ Cancer
Lenvatinib Plus Pembrolizumab Improves Survival in Advanced/Recurrent Endometrial Cancer
2 Commerce Drive
Cranbury, NJ 08512